Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial

Wheeler, DC; Stefansson, BV; Jongs, N; Chertow, GM; Greene, T; Hou, FF; McMurray, JJV; Correa-Rotter, R; Rossing, P; Toto, RD; Sjostrom, CD; Langkilde, AM; Heerspink, HJL

Wheeler, DC (corresponding author), UCL, Dept Renal Med, Royal Free Campus, Rowland Hill St, London NW3 2NB, England.

LANCET DIABETES & ENDOCRINOLOGY, 2021; 9 (1): 22

Abstract

Background Dapagliflozin reduces the risk of kidney failure and heart failure in patients with chronic kidney disease. We aimed to investigate the eff......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索